Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Decline in Short Interest

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 208,100 shares, a decline of 24.3% from the November 15th total of 274,900 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily volume of 261,300 shares, the short-interest ratio is presently 0.8 days.

Hedge Funds Weigh In On Tiziana Life Sciences

A hedge fund recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC increased its stake in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 69,387 shares of the company’s stock after purchasing an additional 13,500 shares during the period. Zhang Financial LLC owned approximately 0.07% of Tiziana Life Sciences worth $67,000 as of its most recent filing with the SEC.

Tiziana Life Sciences Stock Performance

Shares of NASDAQ TLSA remained flat at $0.94 during midday trading on Friday. 67,138 shares of the stock were exchanged, compared to its average volume of 263,146. The stock’s fifty day moving average price is $0.95 and its 200 day moving average price is $0.97. Tiziana Life Sciences has a 52 week low of $0.41 and a 52 week high of $1.74.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.